OncoTargets and Therapy (Jul 2020)

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

  • Du L,
  • Zhang L,
  • Li L,
  • Li X,
  • Yan J,
  • Wang X,
  • Fu X,
  • Sun Z,
  • Zhang X,
  • Li Z,
  • Wu J,
  • Yu H,
  • Chang Y,
  • Zhou Z,
  • Nan F,
  • Wu X,
  • Tian L,
  • Zhang M

Journal volume & issue
Vol. Volume 13
pp. 7189 – 7197

Abstract

Read online

Lijun Du, Lei Zhang, Ling Li, Xin Li, Jiaqin Yan, Xinhua Wang, Xiaorui Fu, Zhenchang Sun, Xudong Zhang, Zhaoming Li, Jingjing Wu, Hui Yu, Yu Chang, Zhiyuan Zhou, Feifei Nan, Xiaolong Wu, Li Tian, Mingzhi Zhang Department of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, People’s Republic of ChinaCorrespondence: Mingzhi ZhangDepartment of Oncology, Zhengzhou University First Affiliated Hospital, Lymphoma Diagnosis and Treatment Center of Henan Province, &Ngr;o. 1 Jianshe East Road, Zhengzhou, Henan, People’s Republic of ChinaTel +86 13838565629Fax +86 37166295563Email [email protected]: Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTL) is a specific subtype of peripheral T cell lymphoma (PTCL) with a poor prognosis. To date, there exist no standard therapeutic regimens for relapsed/refractory (R/R) ENKTL. More potent treatment strategies are urgently needed to improve the survival of these patients with R/R ENKTL. Herein, we present three R/R ENKTL patients who failed prior therapies (L-asparaginase containing chemotherapy, radiotherapy or biological-cell therapy, etc.) benefited from the combination regimen comprised of anti-programmed-death-1 (PD-1) antibody toripalimab, chidamide, etoposide, and thalidomide. They received the treatment regimen continuously until the disease progression occurs. As of data collection, two patients achieved complete remission (CR) after 4, 6 cycles of treatment, respectively, and another patient was evaluated as partial remission (PR) after 2 cycles. Treatment-related adverse events (AEs) mainly presented grade 2∼ 3 leukocytopenia and anemia, which were controllable. It follows that PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) regimen may be a promising choice for patients with R/R ENKTL and warrants further investigation.Keywords: NK/T-cell lymphoma, relapsed/refractory, PD-1, chidamide, targeted treatment

Keywords